Evidence map›Paper›PMID 36369039›Full record

ArticleJournal of nanobiotechnology2022

A mitochondria-targeted molecular phototheranostic platform for NIR-II imaging-guided synergistic photothermal/photodynamic/immune therapy.

Sha Yang, Gui-Long Wu, Na Li, Minghui Wang, Peixian Wu, Yuxuan He, Wei Zhou, Hao Xiao, Xiaofeng Tan, Li Tang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Triple-Functional CuAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Mitochondrial Reactive Oxygen Species (mROS) Generation and Cancer:International journal of nanomedicine · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sha YangCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Gui-Long WuCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Na LiCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Minghui WangCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Peixian WuCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Yuxuan HeCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Wei ZhouCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Hao XiaoCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China.
Xiaofeng TanCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China. tanxiaofeng@usc.edu.cn.
Li TangCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China. tanglicq@outlook.com.
Qinglai YangCenter for Molecular Imaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, 421001, Hunan, China. qingyu513@usc.edu.cn.
University of South China · CNHainan Normal University · CN

Funding

financial supports Scientific Research Fund of Hunan Provincial Education Department 19C1711Key Research and Development Program of Hunan Province, China 2022SK2053National Science Foundation of China 81801749Natural Science Foundation of Hunan Province of China 2022JJ40360Natural Science Foundation of Hunan Province of China 2022JJ40361Science and Technology Innovation Program of Hunan Province "Huxiang Young Talents Plan" 2021RC3106
6 · The paper itself

Abstract

Phototherapy is a conducive and non-invasive strategy for cancer therapy under light irradiation. Inspiringly, fluorescence imaging in the second near-infrared window (NIR-II, 1000-1700 nm) holds a great promise for imaging-guided phototherapy with deep penetration and high spatiotemporal resolution. However, most phototherapeutics still face great challenges, including complicated synthesis of agents, potential biotoxicity and unsatisfied therapeutic outcomes. Herein, a near-infrared laser triggered molecular photosensitizer FEPT, modified with triphenylphosphine PEGylation (PEG2000-TPP), is developed for NIR-II imaging-guided mitochondria-targeting synergistic photothermal therapy (PTT)/photodynamic therapy (PDT)/immune therapy (IMT). The mitochondria-targeting photosensitizer FEPT can produce reactive oxygen species (ROS) and hyperpyrexia upon 808 nm laser irradiation, resulting in mitochondrial dysfunction and photo-induced apoptosis via caspase-3 pathway. Phototherapy-induced hyperthermia or ROS triggers the release of immunogenic intracellular substrates from dying tumor cells, thereby promoting the activation of antitumor immunity. Herein, this work provides a practicable strategy to develop a molecular phototheranostic platform for imaging-guided cancer therapy via mitochondria-targeting.

Indexed as

NanoparticlesNeoplasmsPhotochemotherapyCell Line, TumorHumansMitochondriaOptical ImagingPhotosensitizing AgentsPhototherapyPhotothermal TherapyReactive Oxygen SpeciesPhotosensitizing AgentsReactive Oxygen SpeciesImmunogenic cell deathMitochondria-targetingNIR-II imaging-guidedPhotodynamic therapyPhotothermal therapy

Identifiers

PMID36369039
PMCPMC9652787
OpenAlexW4309046305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.